Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 of FAT 75637/B was determined to be greater than 2000 mg/kg body weight.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Study initiation date - 24 February 2021; Experiment start date - 25 February 2021; Experiment completion date - 25 March 2021; Study completion date - 23 June 2021.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Deviations:
- yes
- Remarks:
- See "Any other information on materials and methods incl. tables"
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- no
- Specific details on test material used for the study:
- Test Item: FAT 75637/B TE
Physical Appearance: Light yellow powder
Purity: 99.4 % all organic constituents; 95.0 % main constituent
Batch No: AT-0063765400
Manufactured Date: 21st April 2020
Expiry Date: May 27th, 2025 - Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Rats were housed under standard laboratory conditions, air conditioned with adequate fresh air supply (14.5 to 14.9 air changes/hour). Environment: temperature 21 to 24 °C, relative humidity 65 to 67 %, 12 hours light and 12 hours dark cycle. The maximum and minimum temperature and relative humidity in the experimental room were recorded once daily. The relative humidity in the experimental room was calculated from dry and wet bulb temperature recordings.
- Route of administration:
- oral: gavage
- Vehicle:
- other: Milli-Q water
- Details on oral exposure:
- Groups of animals of a single sex are dosed in a stepwise procedure using the fixed doses of 300 and 2000 mg/kg. The initial dose level was selected on the basis of a sighting study as the dose expected to produce some signs of toxicity without causing severe toxic effects or mortality. Further groups of animals were dosed at higher dose depending on the presence or absence of the signs of toxicity or mortality. This procedure continues until the dose causing evident toxicity or no more than one death is identified or when no effects are seen at the highest dose or when deaths occur at the lowest dose.
- Doses:
- As there was no complete available toxicology information about test item. Hence, the study was initiated with starting dose of 300 mg/kg body weight as sighting study. The test was started as per Annex 2 of the OECD Test guideline. Based on result of sighting study the main study was performed by using 4 animals of same sex.
- Control animals:
- no
- Details on study design:
- The dose formulation was prepared by using Milli-Q water and administered as a single oral gavage to overnight fasted (16 to 18 hours) female rat (G1-sighting study) at the dose of 300 mg/kg body weight. The rat was normal and there was no pre-terminal death observed. based on the treatemnt schedule, the treatment was started by dosing one female rat at the dose of 2000 mg/kg body weight (G2- sighting study). The rat was normal and there was no pre-terminal death observed. Hence, treatment was continued by dosing four additional female rats at the higher dose of 2000 mg/kg body weight (G2-main study). All rats were normal and there were no pre-terminal death observed. The prepared dose formulation was administered at the dose volume of 10 mL/kg bodyweight. The rats were observed for mortality and clinical signs for 14 days post treatment. Body weights were recorded prior to dosing on day 1 and again on days 8 and 15. Necropsy was performed for all the surviving rats. All surviving rats gained weight during experimental period. There were no gross pathological changes observed at necropsy.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no pre-terminal deaths.
- Clinical signs:
- other: There were no clinical signs
- Gross pathology:
- There were no gross pathological changes at necropsy in the terminal sacrifice rats
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on the results of the present study, the LD50 of test item, FAT 75637/B TE is greater than 2000 mg/kg body weight.
- Executive summary:
The acute oral toxicity study with FAT 75637/B in Wistar rats was conducted to assess the toxicological profile of the test item. This study was conducted according to OECD test guideline 420 in a GLP certified laboratory. The dose formulation was prepared by using Milli-Q water and administered as a single oral gavage to overnight fasted (16 to 18 hours) female rat (G1-sighting study) at the dose of 300 mg/kg body weight. The rat was normal and there was no pre-terminal death observed. According to the treatment schedule, the treatment was started by dosing one female rat at the dose of 2000 mg/kg body weight (G2- sighting study). The rat was normal and there was no pre-terminal death observed. Hence, the treatment was continued by dosing four additional female rats at the higher dose of 2000 mg/kg body weight (G2-main study). All rats were normal and there were no pre-terminal death observed. The prepared dose formulation was administered at the dose volume of 10 mL/kg body weight. The rats were observed for mortality and clinical signs for 14 days post treatment. Body weights were recorded prior to dosing on day 1 and again on days 8 and 15. Necropsy was performed for all the surviving rats. All surviving rats gained weight during experimental period. There were no gross pathological changes observed at necropsy. The dose formulation analysis was performed for the G1-(300 mg/kg body weight) and G2-(2000 mg/kg body weight). The obtained results of dose formulation analysis for 30 mg/mL and 200 mg/mL were found to be with in the acceptable limit (85-115 %). Based on the results of the present study, The LD50 of test item, FAT 75637/B is greater than 2000 mg/kg body weight.
Reference
Body weight:
Group and Dose (mg/kg body weight) |
Rat No. |
Sex | Body weight (g) |
No. dead/ No. tested |
Pre-terminal deaths (%) | |||||
Initial (Day 1) |
8th day | Weight change (day 8 – Initial) |
15th day | Weight change (day 15 – Initial) |
At Death | |||||
G1(Sighting study) 300 | Rw8001 | F | 230.1 | 245.4 | 15.3 | 260.1 | 30.0 | NA | 0/1 | 0 |
G2 (Sighting study) 2000 | Rw8002 | F | 249.9 | 263.5 | 13.6 | 274.8 | 24.9 | NA | 0/1 | 0 |
G2 (Main study) 2000 | Rw8003 | F | 240.1 | 252.8 | 12.7 | 268.4 | 28.3 | NA |
0/4 | 0 |
Rw8004 | F | 229.8 | 240.7 | 10.9 | 257.3 | 27.5 | NA | |||
Rw8005 | F | 227.0 | 238.8 | 11.8 | 256.8 | 29.8 | NA | |||
Rw8006 | F | 239.2 | 250.1 | 10.9 | 265.8 | 26.6 | NA |
Summary of stability and homogeneity test
Stability results
Test Item Name: FAT 75637/B; Test Item Code:H009-1; Study No:G20923; Vehicle : Milli-Q Water
Experimental Period: 24 hours
Claimed Concentration (mg/mL) | Sampling Time Point (hour) | Analyzed Test Item Concentration (mg/mL) | Analyzed Test Item Conc(mg/mL) (Mean ± SD) %RSD | % Change over ‘0’ day | |||||
Top | Middle | Bottom | |||||||
R 1 | R 2 | R 1 | R 2 | R 1 | R 2 | ||||
0.025 | 0 | 0.019 | 0.020 | 0.019 | 0.019 | 0.018 | 0.019 | 0.02 ± 0.001 (5.26) | NA |
24 | 0.019 | 0.017 | 0.017 | 0.017 | 0.019 | 0.019 | 0.02 ± 0.001 (5.36) | 0.00 | |
250.13 | 0 | 230.6 | 239.5 | 230.4 | 224.4 | 239.2 | 233.5 | 232.9 ± 5.79 (2.49) | NA |
24 | 254.0 | 251.3 | 254.0 | 252.2 | 263.2 | 254.4 | 254.9 ± 4.27 (1.67) | 9.45 | |
Acceptance criteria: Stability of the formulations was considered acceptable if mean results are within ± 15.0% from the mean initial stability (homogeneity) time point and formulations will be considered re-suspendable if mean %RSD is equal to or less than 10.0% |
Where, R = replication, NA = Not applicable
Conclusion: The test item, FAT 75637/B was observed to be stable in the vehicle at dose concentrations of 0.025 and 250.13 mg/mL up to 24 hours when stored at room temperature.
Homogeneity results Test Item Name: FAT 75637/B
Claimed concentration (mg/mL) |
Layer | Analyzed test item concentration (mg/mL) | Mean % agreement with claimed concentration in each layer | Overall mean ± s.d. of analyzed testitem concentration (mg/mL) | Accuracy of overall mean of each dose (%) | Overall %RSD | ||
R1 | R2 | Mean | ||||||
0.0205 | Top | 0.019 | 0.020 | 0.02 | 95.1 | 0.019 ± 0.001
| 92.7 | 3.334 |
Middle | 0.019 | 0.019 | 0.02 | 92.7 | ||||
Bottom | 0.018 | 0.019 | 0.02 | 90.3 | ||||
250.13 | Top | 230.6 | 239.5 | 235.1 | 94.0 | 232.9 ± 5.79 | 93.1 | 2.490 |
Middle | 230.4 | 224.4 | 227.4 | 90.9 | ||||
Bottom | 239.2 | 233.5 | 236.4 | 94.5 |
Note: R1, R2 denote replications
*Overall mean ± s.d. should be calculated using all the replicate values of all the layers.
Conclusion: The test item, FAT 75637/B was observed to be homogeneous in the vehicle at dose concentrations of 1.038 and 250.1 mg/mL
Dose Formulation Analysis Results
Study No: G20923 Study Code : AOR Date of analysis: 11 February 2021
Claimed Conc. | Sample code | Analyzed (mg/mL) | Mean Analyzed | Concentration | % Agreement with Claimed Conc. | Mean % Agreement with Claimed Conc. in each layer | % Agreement | ||||
Mean Analyzed Conc (mg/mL) | SD | % RSD | Mean of % Agreement with Claimed Conc. | SD | % RSD | ||||||
200 | G1TR1 | 191.7 | 1932 | 197.8
| 4.89
| 2.47 | 95.8 | 96.6 | 98.9
| 2.44
| 2.47 |
G1TR2 | 194.8 | 97.4 | |||||||||
G1MR1 | 195.3 | 197.8 | 97.6 | 98.9 | |||||||
G1MR2 | 200.3 | 100.1 | |||||||||
G1BR1 | 199.6 | 202.5 | 99.8 | 101.2 | |||||||
G1BR2 | 205.4 | 102.7 | |||||||||
Acceptance Criteria: Formulations will be considered acceptable if the mean results (calculated using all the replicate values) of all the layers and mean of each layer are within ±15.0 % of the claimed concentration and the relative standard deviation (% RSD, calculated using all the replicate values) of assay of top, middle and bottom layers (RSD) is equal to or less than 10.0 %. |
Note: No peak was detected at the retention time of the analyte in the vehicle sample. The obtained results were within the acceptance criteria
Individual clinical signs, dose administration and necropsy findings
Group and Dose (mg/kg body weight) | Date and time of administration | Rat No. | Sex | Body weight (Day 1) (g) | Total volume administered (mL) | Day of observation | ||||
Day 1 | ||||||||||
30 min | 1hour | 2 hours | 3 hours | 4 hours | ||||||
G1 (Sighting study) 300 | 03 March 2021 11:40 AM to 11:41 AM
| Rw8001 | F | 230.4 | 2.3 | N | N | N | N | N |
G2 (Sighting study) 2000 | 09 March 2021 11:52 AM to 11:53 AM
| Rw8002 | F | 249.9 | 2.5 | N | N | N | N | N |
G2 (Main study) 2000 | 11 March 2021 12:02 AM to 12:03 AM | Rw8003 | F | 240.1 | 2.4 | N | N | N | N | N |
Rw8004 | F | 229.8 | 2.3 | N | N | N | N | N | ||
Rw8005 | F | 227.0 | 2.3 | N | N | N | N | N | ||
Rw8006 | F | 239.2 | 2.4 | N | N | N | N | N |
F: Female N: Normal min: minutes mg: milligrams kg: kilograms mL: millilitre NAD: No Abnormality Detected
Individual clinical signs, dose administration and necropsy findings:
Group and Dose (mg/kg body weight) | Rat No. | Sex | Day of observation | NecropsyFindings | |||||||||||||
2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ||||
G1 (Sighting study) 300 | Rw8001
| F | N | N | N | N | N | N | N | N | N | N | N | N | N | N | NAD |
G2 (Sighting study) 2000 | Rw8002
| F | N | N | N | N | N | N | N | N | N | N | N | N | N | N | NAD |
G2 (Main study) 2000 | Rw8003
| F | N | N | N | N | N | N | N | N | N | N | N | N | N | N | NAD |
Rw8004
| F | N | N | N | N | N | N | N | N | N | N | N | N | N | N | NAD | |
Rw8005
| F | N | N | N | N | N | N | N | N | N | N | N | N | N | N | NAD | |
Rw8006
| F | N | N | N | N | N | N | N | N | N | N | N | N | N | N | NAD |
F: Female N: Normal min: minutes mg: milligrams kg: kilograms mL: millilitre NAD: No Abnormality Detected
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Good quality database. Klimisch rating 1.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because the substance does not meet the criteria for classification as acute toxicity or STOT SE by the oral route and no systemic effects have been observed in in vivo studies with dermal exposure (e.g. skin irritation, skin sensitisation)
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity
The acute oral toxicity study with FAT 75637/B in Wistar rats was conducted to assess the toxicological profile of the test item. This study was conducted according to OECD test guideline 420 in a GLP-certified laboratory. The dose formulation was prepared by using Milli-Q water and administered as a single oral gavage to overnight fasted (16 to 18 hours) female rat (G1-sighting study) at the dose of 300 mg/kg body weight. The rat was normal and there was no pre-terminal death observed. The treatment was conducted by dosing one female rat at the dose of 2000 mg/kg body weight (G2- sighting study). The rat was normal and there was no pre-terminal death observed. Hence, the treatment was continued by dosing four additional female rats at the higher dose of 2000 mg/kg body weight (G2-main study). All rats were normal and there were no pre-terminal death observed. The prepared dose formulation was administered at the dose volume of 10 mL/kg body weight. The rats were observed for mortality and clinical signs for 14 days post treatment. Body weights were recorded prior to dosing on day 1 and again on days 8 and 15. Necropsy was performed for all the surviving rats. All surviving rats gained weight during experimental period. There were no gross pathological changes observed at necropsy. The dose formulation analysis was performed for the G1-(300 mg/kg body weight) and G2-(2000 mg/kg body weight). The obtained results of dose formulation analysis for 30 mg/mL and 200 mg/mL were found to be with in the acceptable limit (85-115 %). Based on the results of the present study, The LD50 of test item, FAT 75637/B is greater than 2000 mg/kg body weight.
Acute inhalation toxicity
Currently no study to assess the acute inhalation toxicity potential of HJP 2453 is available. The calculated value for vapour pressure was found to be 6.7E-7 Pa at 25 °C. Hence, the substance is considered to have low volatility. Synthesis and spray drying of this chemical is performed in a closed process; the final product consists of non-dusty granules. Hence, the use of this substance will not result in aerosols, particles or droplets of an inhalable size, so exposure to humans via the inhalation route will be unlikely to occur. Based on column 2, ‘Specific rules for adaptation from column 1’ of the table given in REACH Annex VII, the study on acute inhalation toxicity only needs to be conducted if an exposure via inhalation is to be expected, based on vapour pressure and/or the likelihood of an exposure to aerosols, particles or droplets. Referring to the expected low volatility of the substance, the fact that the chemical is imported into the EU in a formulated form as a dust-free powder or as a granulate, the exposure via inhalation is considered to be unlikely. The chemical showed low toxicity potential in the available acute oral toxicity study (LD50: >2000 mg/kg bw), with no systemic toxicity being seen, hence it does not need to be classified STOT SE and low toxicity is expected for this chemical via the inhalation route. Taking into consideration the above arguments, low toxicity potential is expected on acute exposure of HJP 2453 via inhalation route and hence testing by the inhalation route was considered scientifically not necessary.
Acute dermal toxicity
Currently no study to assess the acute dermal toxicity potential of HJP 2453 is available. However, the molecular weight of HJP 2453 is 356.4 g/mol, indicating dermal absorption may be limited. It has water solubility of <50 microgram/L, indicating poorly solubility in water will further limit the partition from the stratum corneum into the epidermis. Hence, the dermal uptake for the substance will be low. The chemical showed low toxicity potential in the available acute oral toxicity study (LD50: >2000 mg/kg bw), with no systemic toxicity observed, hence, it does not need to be classified as STOT SE. Similarly, absence of systemic toxicity in skin irritation and sensitisation studies, further supports the conclusion that no adverse effects are expected for the chemical via the dermal route. Further, experience with similar chemical substances has demonstrated that it is very unlikely that toxicity related to the intrinsic properties of the chemical only show up upon dermal exposure and not after systemic application. Taking above arguments into consideration, low toxicity is expected on acute dermal exposure of HJP 2453 and testing by the dermal route was considered scientifically not necessary.
Justification for classification or non-classification
The substance does not need to be classified for acute toxicity according to CLP (Regulation (EC) No 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.